196 related articles for article (PubMed ID: 25464386)
1. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.
Lerman DM; Monument MJ; McIlvaine E; Liu XQ; Huang D; Monovich L; Beeler N; Gorlick RG; Marina NM; Womer RB; Bridge JA; Krailo MD; Randall RL; Lessnick SL;
Pediatr Blood Cancer; 2015 May; 62(5):759-65. PubMed ID: 25464386
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
Tsuchiya T; Sekine K; Hinohara S; Namiki T; Nobori T; Kaneko Y
Cancer Genet Cytogenet; 2000 Jul; 120(2):91-8. PubMed ID: 10942797
[TBL] [Abstract][Full Text] [Related]
3. High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcoma.
Lynn M; Wang Y; Slater J; Shah N; Conroy J; Ennis S; Morris T; Betts DR; Fletcher JA; O'Sullivan MJ
Diagn Mol Pathol; 2013 Jun; 22(2):76-84. PubMed ID: 23628818
[TBL] [Abstract][Full Text] [Related]
4. Ewing sarcoma: a tough road to clinically relevant biomarkers.
Shukla N
Pediatr Blood Cancer; 2015 May; 62(5):741-2. PubMed ID: 25586427
[No Abstract] [Full Text] [Related]
5. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.
Tirode F; Surdez D; Ma X; Parker M; Le Deley MC; Bahrami A; Zhang Z; Lapouble E; Grossetête-Lalami S; Rusch M; Reynaud S; Rio-Frio T; Hedlund E; Wu G; Chen X; Pierron G; Oberlin O; Zaidi S; Lemmon G; Gupta P; Vadodaria B; Easton J; Gut M; Ding L; Mardis ER; Wilson RK; Shurtleff S; Laurence V; Michon J; Marec-Bérard P; Gut I; Downing J; Dyer M; Zhang J; Delattre O;
Cancer Discov; 2014 Nov; 4(11):1342-53. PubMed ID: 25223734
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT.
Brownhill SC; Taylor C; Burchill SA
Br J Cancer; 2007 Jun; 96(12):1914-23. PubMed ID: 17533400
[TBL] [Abstract][Full Text] [Related]
7. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.
Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ
Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303
[TBL] [Abstract][Full Text] [Related]
8. Detection and Correlation of Single and Concomitant
Pessôa IA; Amorim CK; Ferreira WAS; Sagica F; Brito JR; Othman M; Meyer B; Liehr T; de Oliveira EHC
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151164
[TBL] [Abstract][Full Text] [Related]
9. Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group.
Cash T; McIlvaine E; Krailo MD; Lessnick SL; Lawlor ER; Laack N; Sorger J; Marina N; Grier HE; Granowetter L; Womer RB; DuBois SG
Pediatr Blood Cancer; 2016 Oct; 63(10):1771-9. PubMed ID: 27297500
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of tumor suppressor proteins in the Ewing family of tumors.
Maitra A; Roberts H; Weinberg AG; Geradts J
Arch Pathol Lab Med; 2001 Sep; 125(9):1207-12. PubMed ID: 11520274
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of INK4A deletion in Ewing sarcoma.
Wei G; Antonescu CR; de Alava E; Leung D; Huvos AG; Meyers PA; Healey JH; Ladanyi M
Cancer; 2000 Aug; 89(4):793-9. PubMed ID: 10951342
[TBL] [Abstract][Full Text] [Related]
12. Risk stratification by somatic mutation burden in Ewing sarcoma.
Liu KX; Lamba N; Hwang WL; Niemierko A; DuBois SG; Haas-Kogan DA
Cancer; 2019 Apr; 125(8):1357-1364. PubMed ID: 30602061
[TBL] [Abstract][Full Text] [Related]
13. Age-dependent prognostic effects of genetic alterations in glioblastoma.
Batchelor TT; Betensky RA; Esposito JM; Pham LD; Dorfman MV; Piscatelli N; Jhung S; Rhee D; Louis DN
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):228-33. PubMed ID: 14734474
[TBL] [Abstract][Full Text] [Related]
14. Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia.
Agarwal M; Bakhshi S; Dwivedi SN; Kabra M; Shukla R; Seth R
Pediatr Blood Cancer; 2018 Jun; 65(6):e27001. PubMed ID: 29446543
[TBL] [Abstract][Full Text] [Related]
15. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A.
Elnenaei MO; Gruszka-Westwood AM; A'Hernt R; Matutes E; Sirohi B; Powles R; Catovsky D
Haematologica; 2003 May; 88(5):529-37. PubMed ID: 12745272
[TBL] [Abstract][Full Text] [Related]
16. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma.
Mackintosh C; Ordóñez JL; García-Domínguez DJ; Sevillano V; Llombart-Bosch A; Szuhai K; Scotlandi K; Alberghini M; Sciot R; Sinnaeve F; Hogendoorn PC; Picci P; Knuutila S; Dirksen U; Debiec-Rychter M; Schaefer KL; de Álava E
Oncogene; 2012 Mar; 31(10):1287-98. PubMed ID: 21822310
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma.
Casey DL; Pitter KL; Wexler LH; Slotkin EK; Gupta GP; Wolden SL
Br J Cancer; 2021 Aug; 125(4):576-581. PubMed ID: 34017087
[TBL] [Abstract][Full Text] [Related]
18. Loss of p16
Aesif SW; Aubry MC; Yi ES; Kloft-Nelson SM; Jenkins SM; Spears GM; Greipp PT; Sukov WR; Roden AC
J Thorac Oncol; 2017 May; 12(5):860-871. PubMed ID: 28179162
[TBL] [Abstract][Full Text] [Related]
19. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
Biernat W; Debiec-Rychter M; Liberski PP
Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
[TBL] [Abstract][Full Text] [Related]
20. The prognostic signature of the somatic mutations in Ewing sarcoma: from a network view.
Zhang Y; Song J; Shi Q; Song X; Shen L; Zhou J; Shao J
Jpn J Clin Oncol; 2019 Jul; 49(7):604-613. PubMed ID: 30927420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
